Small lymphocytic lymphoma (SLL) is a form of chronic lymphoproliferative disease belonging to the group of non-Hodgkin lymphomas. This disease develops from mature, small lymphocytes that tend to accumulate in the lymph nodes and other organs of the lymphatic system, such as the spleen and bone marrow. Clinically, SLL manifests itself as enlarged lymph nodes and can also lead to systemic symptoms such as fever, sweating, weight loss, and fatigue. The underlying mechanism of pathogenesis is the activation of various signaling pathways that promote uncontrolled division and survival of lymphocytes, which ultimately leads to clinically significant symptoms.
History of the disease and interesting historical facts
The history of studying small lymphocytic lymphoma is closely related to the development of oncology and hematology. The first mentions of lymphomas as independent diseases date back to the early 19th century, when physicists and pathologists began to systematically describe various tumor formations. In 1966, the term "small lymphocytic lymphoma" was introduced, which is used to classify this disease. Dr. R. H. Rappaport and his colleagues first presented a consolidated classification of lymphomas, which became the basis for further research. Interestingly, in different historical periods, diseases were described with various clinical manifestations, as well as under different names, which indicated the complexity of diagnosis and morphological heterogeneity of this group of lymphomas.
Epidemiology
The epidemiology of small lymphocytic lymphoma is characterized by its high prevalence in the population. According to national registries, the incidence of SLL is approximately 4.7 cases per 100,000 people per year, which places it in the leading places among non-Hodgkin's lymphomas. The dependence of incidence on age is also important: the disease is more common in people over 60 years old, and in this age group, an increase in incidence is observed up to 15 cases per 100,000. Men are slightly more likely to develop SLL than women, with a ratio of 1.5:1. This disease is typical of high-income countries and is more common among people of European and American descent.
Genetic predisposition to this disease
Genetic studies show that structural and numerical changes in chromosomes play an important role in the pathogenesis of small lymphocytic lymphoma. The main changes are considered to be deletions and transpositions, as well as mutations in genes such as TP53, IGH and ATM. Of particular interest is the presence of chromosome 13 - its deletions are observed in more than 50% patients with SLL. It was also found that the presence of a mutation in the TP53 gene is associated with a worse prognosis and aggressiveness of the disease. These data allow doctors to conduct genetic testing to determine the risk of developing the disease.
Risk factors for the development of this disease
Risk factors that contribute to the development of small lymphocytic lymphoma include the following:
- Age: The risk is greatest in people over 60 years of age.
- Gender: Men have a higher risk of developing the disease than women.
- Genetic predisposition: having close relatives with cancer, particularly lymphomas.
- Immune disorders: Chronic diseases such as HIV or autoimmune diseases may lead to an increased risk compared to the general population.
- Chemical exposure: Contact with pesticides, solvents, and some levels of radiation have been associated with an increased risk of developing the disease.
Diagnosis of this disease
Diagnosis of small lymphocytic lymphoma requires a comprehensive approach and includes multiple methods. The main symptoms include enlargement of the lymph nodes, spleen, and liver. Laboratory studies show abnormalities in the clinical blood test, such as anemia, thrombocytopenia, and lymphocytosis. Radiological studies (ultrasound, CT, MRI) help to identify the size and overall picture of enlarged lymph nodes. Immunophenotyping of tissue samples obtained by biopsy helps in clarifying the type of lymphoma and differential diagnosis with other diseases. Thus, before treatment, it is important to exclude differential diagnosis with chronic lymphocytic leukemia (CLL) and other types of lymphoma.
Treatment
Treatment of small lymphocytic lymphoma can be either observational or active, depending on the stage of the disease and the general condition of the patient. In the initial stages, when the disease is asymptomatic, only regular observation without active intervention is possible. If the disease progresses, chemotherapy becomes the mainstay, in particular, the CHOP or FCR regimens. In addition, immune drugs such as rituximab are used, which are aimed at destroying tumor cells. Surgery is mainly used for diagnostic purposes, but in some cases it can be used to remove large formations. There is also the possibility of stem cell transplantation in case of relapses or aggressive forms of the disease.
List of medications used to treat this disease
- Rituximab.
- Chlorambucil.
- Cyclophosphamide.
- Doxorubicin.
- Prednisolone.
- Obinarizumab.
- Bendamustine.
Disease monitoring
Disease monitoring includes regular examinations to assess the effectiveness of treatment and identify possible relapses. Includes clinical examinations, blood tests, and imaging methods. The prognosis of the disease depends on the stage and the presence of complications. In most cases, the disease can be asymptomatic for a long time, but aggressive forms with a rapidly progressive course are also possible. Complications may include infections, anemia, and thrombocytopenia. It is important to note that the survival rate depends on early diagnosis and adequate treatment.
Age-related features of the disease
Small lymphocytic lymphoma presents differently in different age groups. In older patients, the disease often has a milder course, but serious complications are possible due to weakened immune systems and comorbidities. In younger people, SLL presents with a more aggressive course and a poor response to standard treatment regimens, which requires a more aggressive approach to treatment in these age groups. In addition, SLL is extremely rare in children, and in such cases, associated genetic diseases are usually observed.
Questions and Answers
- What is small lymphocytic lymphoma?
Answer: This is a form of chronic lymphoproliferative disease characterized by the accumulation of mature small lymphocytes in the lymph nodes and other organs. - What are the main symptoms of the disease?
Answer: The main symptoms include swollen lymph nodes, weight loss, sweating and fatigue. - What factors may increase the risk of developing SLL?
Answer: Risk factors include age, genetic predisposition, gender, exposure to chemicals, and the presence of immune disorders. - How is small lymphocytic lymphoma diagnosed?
Answer: Diagnostics includes clinical examination, laboratory tests, radiological methods and morphological examination of biopsies. - What is the prognosis for patients with SLL?
Answer: The prognosis depends on the stage of the disease and the quality of treatment; with early diagnosis, survival can be quite high.
